FLNA

Filana Therapeutics Inc

0.4527

Nov 06 • 3:59 PM ET +0.0017 (0.38%)

0.4500

Aftermarket • 7:52 PM ET -0.0027 (-0.60%)

Healthcare Biotechnology USA Nano NASD

Nov 05, 10:16 AMFilana Therapeutics reports Q3 2026 results with non-GAAP EPS $-0.22 and revenue $0, beats estimates after FDA lifts simufilam IND hold

Peers: ANVS CGTX INMB ABOS CRVO PMN ACIU PRTA ALZN BIIB

| Held by: VTI VXF VHT IWC BTEC

Scroll to Statements

Index	-
Market Cap	22.76M
Enterprise Value	-55.48M
Income	-42.20M
Sales	0.00M
Book/sh	1.16
Cash/sh	1.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Dec 13, 2012
Dividend Gr. 3/5Y	- -
Payout	-
Employees	20
IPO	Jul 14, 2000

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.39
P/C	0.29
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.91
Current Ratio	1.91
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.87
EPS next Y	-
EPS next Q	-0.26
EPS this Y	53.72%
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	0.23% -50.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	60.29%
Sales Y/Y TTM	-
EPS Q/Q	1.07%
Sales Q/Q	-
Earnings	Nov 05 BMO
EPS/Sales Surpr.	10.20% -

Insider Own	2.88%
Insider Trans	38.16%
Inst Own	26.11%
Inst Trans	-3.40%
ROA	-36.73%
ROE	-60.48%
ROIC	-72.79%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-29.54%
SMA50	-39.94%
SMA200	-65.63%
Trades

Shs Outstand	50.07M
Shs Float	-
Short Float	-
Short Ratio	2.78
Short Interest	5.60M
52W High	3.45 -86.88%
52W Low	0.45 0.60%
Volatility	13.78% 7.80%
ATR (14)	0.06
RSI (14)	27.06
Beta	-0.36
Rel Volume	0.30
Avg Volume	2.01M
Volume	608,299

Perf Week	-27.22%
Perf Month	-44.36%
Perf Quarter	-54.61%
Perf Half Y	-65.18%
Perf YTD	-77.14%
Perf Year	-84.71%
Perf 3Y	-97.88%
Perf 5Y	-99.50%
Perf 10Y	-87.57%
Recom	1.00
Target Price	6.50
Prev Close	0.45
Price	0.45
Change %	0.38%

Consensus

Strong Buy

Avg. Price Target

$6.50

Implied Upside

+1,335.8%

Analysts4incl. previous ratings

Rating Distribution1 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 26, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Oct 08, 2024	Upgrade	HH.C. Wainwright	Neutral → Buy	$116	+25,524.0%
Jul 01, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Nov 16, 2022	Downgrade	RB. Riley Securities	Buy → Neutral	$44	+9,619.5%
Jul 15, 2021	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$100	+21,989.7%
Jul 07, 2021	Reiterated	MMaxim Group	Buy	$80 → $190	+41,870.4%
Apr 27, 2021	Initiated	RB. Riley Securities	Buy	$78	+17,130.0%
Feb 16, 2021	Reiterated	HH.C. Wainwright	Buy	$20 → $66	+14,479.2%
Oct 23, 2020	Initiated	CCantor Fitzgerald	Overweight	$24	+5,201.5%
Sep 23, 2020	Upgrade	HH.C. Wainwright	Neutral → Buy	$20	+4,317.9%
May 18, 2020	Downgrade	HH.C. Wainwright	Buy → Neutral
May 15, 2020	Downgrade	MMaxim Group	Buy → Hold
Jan 10, 2020	Reiterated	MMaxim Group	Buy	$3 → $12	+2,550.8%

Nov-05-26 08:00AM	Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update (GlobeNewswire) -21.15%
Oct-28-26 08:00AM	Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells (GlobeNewswire)
Oct-09-26 08:00AM	Filana Therapeutics to Participate in the 2026 Maxim Growth Summit (GlobeNewswire)
Sep-22-26 08:00AM	Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy (GlobeNewswire) +39.28%
Aug-12-26 02:21PM	Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
08:00AM	Loading…
Jul-29-26 08:00AM	Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-07-26 08:00AM	Filana Therapeutics Reports Q1 2026 Financial Results and Business Update (GlobeNewswire) -5.56%
May-05-26 08:00AM	Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII (GlobeNewswire)
Apr-15-26 08:00AM	Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data (GlobeNewswire)
Mar-12-26 08:00AM	Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -6.70%
Feb-19-26 08:00AM	Cassava Announces Closure of U.S. Department of Justice Investigation (GlobeNewswire)
Jan-13-26 08:00AM	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease (GlobeNewswire)
Dec-24-25 11:51AM	HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Dec-23-25 08:00AM	Cassava Announces Agreement to Settle Securities Class Action Litigation (GlobeNewswire) -7.56%
Nov-25-25 07:39AM	Cassava Pops After CEO Buys 150,000 Shares (GuruFocus.com)
08:00AM	Loading…
Nov-12-25 08:00AM	Cassava Reports Q3 2025 Financials Results and Provides Business Update (GlobeNewswire)
Oct-22-25 04:05PM	Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire) -7.04% +5.68%
08:00AM	Cassava Sciences Appoints Dawn C. Bir to the Board of Directors (GlobeNewswire)
Sep-24-25 04:58AM	Cassava, Accenture to deploy sovereign AI solutions across Africa (Verdict)
Sep-23-25 12:13PM	Cassava Boss Buys Big As Stock Collapses (GuruFocus.com) +46.98%
Aug-25-25 08:00AM	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 07:30AM	Cassava Reports Q2 2025 Financials Results and Provides Business Update (GlobeNewswire) +5.70%
Aug-07-25 07:30AM	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer (GlobeNewswire) -6.41%
Aug-04-25 07:30AM	Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy (GlobeNewswire) +8.02%
Jun-30-25 07:00AM	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting (GlobeNewswire)
May-08-25 08:00AM	Cassava Reports Q1 2025 Financials Results, Provides Business Update (GlobeNewswire) +8.97%
May-01-25 07:30AM	Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
07:30AM	Cassava Appoints Angelique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
Apr-21-25 04:30PM	Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development (GlobeNewswire) +8.90%
Apr-01-25 09:35AM	Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround (Zacks) -8.00%
10:00AM	Loading…
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks) -9.09%
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks) -7.89%
07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
Mar-25-25 08:05AM	Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (GlobeNewswire) -32.14%
Mar-20-25 06:18PM	Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments (SeekingAlpha)
Mar-05-25 11:20AM	H.C. Wainwright focused on what results from Cassavas ReFocus-ALZ might reveal (TipRanks)
Mar-03-25 07:30AM	Cassava Sciences Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Cassava Sciences Licenses Simufilam Method of Treatment Patent (GlobeNewswire) +13.04%
Jan-16-25 01:56PM	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-13-25 12:15PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-07-25 04:30PM	Cassava Sciences Provides a Business Update (GlobeNewswire) -6.46%
Dec-27-24 05:45AM	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA (PR Newswire)
Dec-16-24 02:55PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky for More Information SAVA (GlobeNewswire)
Nov-25-24 04:15PM	Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops (Investor's Business Daily) -83.78% -10.94%
03:57PM	Cassava Sciences plummets over 80% on Alzheimer's trial fail (Yahoo Finance Video)
09:19AM	Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study (Investopedia)
07:30AM	Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints (GlobeNewswire)
Nov-24-24 08:01PM	Cassava Sciences to Hold Corporate Update on November 25th (GlobeNewswire)
Nov-18-24 08:30AM	Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer (GlobeNewswire)
Nov-07-24 07:55AM	Cassava Sciences Reports Q3 2024 Financial and Operating Results (GlobeNewswire)
Oct-31-24 08:30AM	Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 (GlobeNewswire)
Oct-17-24 09:19PM	Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge (Insider Monkey)
Oct-09-24 08:29AM	Cassava Sciences Advances Alzheimers Trials Amid SEC Settlement (TipRanks)
Sep-27-24 03:36PM	Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims (Yahoo Finance Video) -10.62%
10:10AM	Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims (Investopedia)
Sep-26-24 06:15PM	Cassava Sciences Resolves SEC Investigation (GlobeNewswire)
Sep-24-24 08:30AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire) +9.54%
Sep-09-24 08:30AM	Cassava Sciences Names Rick Barry as Chief Executive Officer (GlobeNewswire)
Sep-03-24 08:31AM	Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 10:44PM	Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks (Insider Monkey)
08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-08-24 08:00AM	Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (GlobeNewswire) -13.84%
Aug-06-24 10:00AM	Cassava Sciences News: Why Is SAVA Stock Trending Today? (InvestorPlace) -13.08%
Aug-05-24 09:01AM	Cassava Sciences Mourns the Death of Board Member Sanford Sandy Robertson (GlobeNewswire) +20.51%
Aug-01-24 08:30AM	Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET (GlobeNewswire) +5.72%
Jul-30-24 08:15AM	Cassava Sciences Announces Expansion of Open-Label Extension Trials (GlobeNewswire)
Jul-17-24 12:26PM	SOUN Stock: Sports Bar Chain Rolls Out Voice Tech From SoundHound AI (InvestorPlace) -29.27%
08:00AM	Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives (GlobeNewswire)
Jul-08-24 04:45PM	3 Healthcare Stocks to Sell in July Before They Crash & Burn (InvestorPlace) +17.38%
Jul-05-24 07:30AM	3 Biotech Stocks to Sell in July Before They Crash & Burn (InvestorPlace) -5.15%
Jul-04-24 07:47AM	Jim Cramer's Latest Stock Portfolio: Top 10 Recommendations (Insider Monkey)
Jul-01-24 03:54PM	Cassava forms committee after US probe, researcher fraud (Yahoo Finance Video)
01:30PM	Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences (The Wall Street Journal)
11:20AM	Planet Labs Layoffs 2024: What to Know About the Latest Planet Job Cuts (InvestorPlace)
10:40AM	SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud (InvestorPlace)
Jun-28-24 06:14PM	Cassava Sciences Adviser Indicted on Fraud Charges (The Wall Street Journal) -34.83%
03:58PM	Cassava Sciences Issues Statement on Former Science Advisor (GlobeNewswire)
Jun-27-24 03:38PM	Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
May-23-24 09:55AM	Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
May-10-24 08:53PM	SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam (GlobeNewswire)
May-08-24 11:00AM	Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution (GlobeNewswire)
May-01-24 09:10AM	Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ (GlobeNewswire)
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-15-24 09:20AM	Redemption Date Announced for Warrants (GlobeNewswire) -12.04%
Mar-25-24 09:13AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire)
Mar-13-24 10:45AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava (PR Newswire)
Mar-04-24 09:15AM	Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference (GlobeNewswire)
Feb-28-24 09:14AM	Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-23-24 11:30AM	CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Feb-08-24 10:39AM	Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial (InvestorPlace)
Feb-07-24 09:08AM	No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months (GlobeNewswire) +7.35%
Feb-05-24 02:35PM	Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-05-24 11:46AM	New SAVAW Warrants Are Trading After Cassava Sciences' Distribution (InvestorPlace)
09:12AM	Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool)
Dec-15-23 06:06PM	Why Cassava Sciences Stock Zoomed 21% Higher This Week (Motley Fool)
Dec-13-23 11:10AM	Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days (Investor's Business Daily)
Dec-12-23 02:02PM	Why Is Cassava Sciences (SAVA) Stock Up 15% Today? (InvestorPlace) +5.96%
09:13AM	Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barry Richard	President & CEO	Sep 29 '26	Buy	0.90	206,813	186,132	1,237,964	Oct 01 07:57 AM
Barry Richard	President & CEO	Sep 30 '26	Buy	0.92	100,000	92,000	1,337,964	Oct 01 07:57 AM
Barry Richard	President & CEO	Sep 28 '26	Buy	0.84	93,091	78,196	1,031,151	Sep 30 04:03 PM
Anderson Robert Eugene Jr	Director	Nov 24 '25	Buy	2.90	8,600	24,940	8,600	Nov 25 04:06 PM
Barry Richard	President & CEO	Nov 20 '25	Buy	2.76	150,000	414,000	938,060	Nov 24 04:02 PM
Barry Richard	President & CEO	Nov 19 '25	Buy	2.75	73,385	201,809	788,060	Nov 20 05:39 PM

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

CEOMr. Richard Jon Barry

Chief Financial OfficerMr. Eric J. Schoen

Chief Operating & Legal OfficerMr. R. Christopher Cook J.D.

Senior Vice President of TechnologyDr. George Thornton Ph.D.

Senior Vice President of Technical OperationsMr. Michael Zamloot

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FLNA

Filana Therapeutics Inc

Upgrade your Finviz experience